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Abstract  
Purpose The etiology of maternal ageing, a common cause of female factor infertility and a rate-limiting step in vitro 
fertilization (IVF) success, remains still unclear. Proteomic changes responsible for the impaired successful pregnancy 
outcome after IVF with aged blastocysts have not been yet evaluated. The objective of this prospective study was to 
employ proteomic techniques and bioinformatic tools to enlight differences at the protein level in blastocoel fluid of 
aged and younger woman.  
Methods Protein composition of human blastocoel fluid isolated by micromanipulation from 46 blastocysts of women 
aged <37 years (group A) and 29 of women aged ≥ 37 years (group B)  have been identified by a shotgun proteomic 
approach based on high resolution nano-liquid chromatography electrospray-ionization-tandem mass spectrometry 
(nLC-ESI-MS/MS) using label free for the relative quantification of their expression levels.  
Results The proteomic analysis leads to the identification and quantification of 148 proteins; 132 and 116 proteins were 
identified in group A and B, respectively. Interestingly, the identified proteins are mainly involved in processes aimed 
at fine tuning embryo implantation and development. Among the 100 proteins commonly expressed in both groups, 17 
proteins are up-regulated and 44 down-regulated in group B compared to group A. Overall, the analysis identified 33 
proteins, which were increased or present only in B while 76 were decreased in B or present only in A. 
Conclusions Data revealed that maternal ageing mainly affects blastocyst survival and implantation through 
unbalancing the equilibrium of the ubiquitin system, known to play a crucial role in fine-tuning several aspects required 
to ensure successful pregnancy outcome.  
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Capsule  
Maternal ageing mainly affects blastocyst survival and implantation through unbalancing the equilibrium of ubiquitin 
system. 
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Introduction 
Embryo implantation requires synchronous development of the blastocyst and the endometrium [1]. During the 
early stages of implantation, the blastocyst enters the uterine cavity apposes and adheres to the endometrial epithelium 
to initiate implantation. It is well established that abnormalities in the bidirectional embryo-endometrial dialogue are 
one of the major cause of infertility resulting in implantation failure [2, 3]. Noteworthy, advancing maternal age 
represents one of the major causes of the altered embryo-endometrial communication [4]. As expected, several large 
studies have reported age-specific outcomes of IVF, and maternal age has clearly been associated with a decline in 
cumulative live birth rates in patients older than 37 [5, 6]. Unfortunately, the molecular changes that occur in the 
endometrium during the “window of receptivity” and the blastocyst contribution have been poorly investigated, due to 
the difficulty and the ethical limitations in studying implantation in humans; thus, no clinically useful markers have 
been identified to assess embryo quality and positive pregnancy outcome [7, 8].  
In the recent years, the development of a wealth of “omic” technologies has opened the way for identifying 
potential markers, although validation of these is still a major issue [9, 10]. In particular, proteomics is an emerging 
powerful technology in the identification of both biomarkers and disease targets, allowing for the detection and 
monitoring of differing conditions or treatments. Although the classic proteomics approach has had limited success in 
the field of embryology [11, 12], the new developments in mass spectrometry have been helpful and the sensitivity of 
this approach has enabled the development of new protocols that are capable of profiling the proteome of small groups 
of mouse embryos [13], and even of single human blastocysts [14-16]. Therefore, several studies have recently 
addressed the analysis of the proteome of the human preimplantation embryo, in particular the ability of the blastocyst 
to secrete and/or consume different proteins in surrounding medium (secretome), in order to communicate with the 
maternal endometrium and proceed with the implantation process [13-15, 17, 18]. Interestingly, degenerating embryos 
presented a different protein expression profile compared to that of developing blastocysts, with a significant alteration 
of numerous biomarkers. Besides surrounding medium, the cells of the blastocyst are exposed to the fluid of the 
blastocoel, an internal cavity that becomes the yolk sac of the developing embryo [19]. Thus, the blastocoel fluid is the 
natural environment of blastocyst growth and the assessment of its protein composition provides an opportunity to 
expand the knowledge of embryonic physiology, including the maternal-embryonic dialog at the time of implantation. 
From a clinical perspective, the analysis of blastocoel fluid is emerging as a crucial topic in the field of reproductive 
medicine aimed at identifying new molecular markers related to highest implantation potential. The ultimate goal is to 
improve blastocyst culture conditions and fertilization rate, as well as to develop an affordable and cost-effective non-
invasive biochemical assay to diagnose blastocyst viability, thus facilitating the move to single embryo transfer. The 
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major problem concerning the analysis of the blastocoel fluid relies on its limited bioavailability (1-8 nl) and, despite 
the fact that recent developments in mass spectrometry allow the identification and characterization of thousands of 
proteins from low microgram levels of protein extracted from tissues or cell cultures [17, 16, 20, 21], the low amounts 
of proteins extractable from blastocoel fluid is still a limiting step in this study.  
Here, by a shotgun proteomic approach and label free quantification, we report for the first time the blastocoel 
fluid proteins that are differentially expressed in 29 collected surplus aged and 46 non-aged blastocysts, taking 37 year 
old women as the cut off parameter to categorized human blastocysts. The differences in the protein profile of 
blastocoel fluid of aged versus non-aged blastocysts relies on the identification of 109 differentially expressed proteins, 
which are mainly involved in processes aimed at fine tuning embryo implantation and development.. Upon validation, 
the suggested key proteins may serve as potential biomarkers of embryo quality and may contribute towards the 
effectiveness of protocols for blastocyst culture management.  
 
Materials and methods 
Patient population 
Written informed consent was obtained from each patient and the study was approved by our local Ethics Commitee. 
All consenting patients undergoing fertility treatment at the Humanitas Fertility Center, Humanitas Research Hospital, 
Rozzano, Italy, with supernumerary blastocysts were included in the study irrespective of the woman’s age (range 
years: 26-41), infertility diagnosis (female or male), ovarian stimulation protocol (use of GnRH agonist or antagonist 
protocols in combination with recombinant and/or highly purified urinary gonadotropins), or performance of standard 
IVF or intracytoplasmic sperm  injection (ICSI).  The study was  part of a trial on blastocoel fluid collection in order to 
test the safety of this procedure on pregnancy outcome [22]. 
 
Blastocyst generation 
Oocytes, sperm and embryos were cultured in the SAGE sequential culture media system (SAGE, Pasadena, USA) at 
37°C in 5% CO2, 5%O2 in nitrogen. Oocytes retrieval was performed 36 h after the administration of recombinant 
human chorionic gonadotropin through transvaginal ultrasonography. Oocytes were inseminated using either standard 
IVF insemination or ICSI; after ICSI, individual oocytes were transferred to a single 25 µl droplets under oil in 
Cleavage Medium supplemented with 10% Serum Protein Substitute (SAGE, Pasadena, USA), while standard IVF-
inseminated oocytes were fertilized in 35 ul Fertilization Medium droplets under oil and transferred on day 1 to the 
Cleavage Medium. Fertilization results were assessed at 16–20 hours post-sperm insemination. On day 3, and in some 
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cases on day 2, 2/3 embryos were selected for transfer to each patient in the study; the embryos in excess of the number 
appropriate for transfer were cultured in single 25 µl droplets under oil in the Blastocyst Medium up to day 5 or day 6, 
and were cryopreserved at the blastocyst stage. Human blastocysts were scored up 120 or 144 hours after insemination 
according to the expansion of the blastocoel cavity and number and integrity of both the inner cell mass (ICM) and 
trophectoderm (TE).  
 
Isolation of the blastocoel fluid and sample collection 
Blastocoel fluids from 75 blastocysts obtained from 52 IVF patients were collected. The blastocoel fluid was isolated by 
micromanipulation using an Olympus X40 (200x) microscope with Narishige manipulators and pipettes (angle: 35°, 
inner diameter: 5.5 um) from Cook (Brisbane, Australia). A droplet of 5-10 µl Blastocyst Medium and a droplet of 3 µl 
water were prepared in an ICSI dish (Falcon-Corning brand, NY, USA) and covered with oil. The blastocysts were 
transferred to the droplet with culture medium and the dish was placed in the micromanipulator. The microinjection 
needle was loaded with water before sampling. The blastocyst was immobilized by the holding pipette with the ICM 
placed toward the holding pipette. The microinjection needle was then gently led in to blastocyst cavity, the fluid was 
aspirated until the blastocyst collapsed and the blastocoel fluid was transferred to the water droplet. After 
micromanipulation the samples were transferred to a labeled PCR tube using a 10 µl pipette and immediately frozen at -
80°C. To obtain adequate protein material for analysis, the samples were collected and analyzed in two pools according 
on the patient’s age: group A (blastocoel fluid from 46 samples of women aged <37 years) and group B (29 samples of 
women aged ≥ to 37 years). Both groups were homogeneous for infertility factor, for dose of gonadotropin 
administrated for ovarian stimulation and for average of oocytes retrieved after induction. 
 
Proteomic analysis  
The proteins of the blastocoel fluid were lysed in a buffer containing 8 M urea, 0.1 M ammonium bicarbonate and the 
complete protease inhibitor cocktail (Roche, Basel, Switzerland). After reduction and derivatization, proteins were 
digested with sequence grade trypsin for 16 hours at 37°C using a protein:trypsin ratio of 1:20. The proteolytic digest 
were desalted using Zip-Tip C18 (Millipore) before mass spectrometric (MS) analysis [23, 24]. LC-ESI-MS/MS analysis 
was performed on a Dionex UltiMate 3000 HPLC System with a PicoFrit ProteoPrep C18 column (200 mm, internal 
diameter of 75 μm) (New Objective, USA). Gradient: 1% ACN in 0.1 % formic acid for 10 min, 1-4 % ACN in 0.1% 
formic acid for 6 min, 4-30% ACN in 0.1% formic acid for 147 min and 30-50 % ACN in 0.1% formic for 3 min at a 
flow rate of 0.3 μl/min. The eluate was electrosprayed into an LTQ Orbitrap Velos (Thermo Fisher Scientific, Bremen, 
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Germany) through a Proxeon nanoelectrospray ion source. The LTQ-Orbitrap was operated in positive mode in data-
dependent acquisition mode to automatically alternate between a full scan (m/z 350-2000) in the Orbitrap (at resolution 
60000, AGC target 1000000) and subsequent CID MS/MS in the linear ion trap of the 20 most intense peaks from full 
scan (normalized collision energy of 35%, 10 ms activation). Isolation window: 3 Da, unassigned charge states: 
rejected, charge state 1: rejected, charge states 2+, 3+, 4+: not rejected; dynamic exclusion enabled (60 s, exclusion list 
size: 200) [25]. Data acquisition was controlled by Xcalibur 2.0 and Tune 2.4 software (Thermo Fisher Scientific, MA 
USA). A sample containing only culture medium, kept as a control (CTR), was also treated and analysed.  
 
Data analysis 
Mass spectra were analyzed using MaxQuant software (version 1.3.0.5). The initial maximum allowed mass deviation 
was set to 20 ppm for monoisotopic precursor ions and 0.5 Da for MS/MS peaks. Enzyme specificity was set to trypsin, 
defined as C-terminal to arginine and lysine excluding proline, and a maximum of two missed cleavages were allowed. 
Carbamidomethylcysteine was set as a fixed modification, N-terminal acetylation, methionine oxidation, and 
asparagine/glutamine deamidation as variable modifications. The spectra were searched by the Andromeda search 
engine against the human Uniprot sequence database (release 22.01.2014). The reversed sequences of the target 
database were used as decoy database. Protein identification required at least one unique or razor peptide per protein 
group. Quantification in MaxQuant was performed using the built in XIC-based label free quantification (LFQ) 
algorithm [26] using fast LFQ. False protein identifications (1% or 5%) [17] were estimated by searching MSMS 
spectra against the corresponding reversed-sequence (decoy) database. The minimum required peptide length was set to 
9 amino acids. Statistical analyses were performed using the Perseus software (version 1.4.0.6). Five technical 
replicates were carried out for each group (A and B) and for the control. Only proteins present and quantified in at least 
3 out of 5 technical repeats and not detected in the sample containing only the culture medium (CTR) were positively 
identified as blastocoel fluid components and used for statistical analyses. Many keratins known to be due to a 
contamination during sample handling, were excluded from the analysis. The intensity of each protein (measured in at 
least 3 replicates in group A and group B) in each replicate are used for the t-test. Proteins were considered 
differentially expressed if they were present only in women aged <37 years (group A) or women aged ≥37 years (group 
B) or showed significant t-test difference (filtered for permutation-based False Discovery Rate of many independent 
hypotheses, cut-off at 5%) between the two groups. The proteins differently expressed in the two groups were clustered 
according to their functions using the DAVID platform [27] filtered for significant Gene Ontology terms: Biological 
Process (GOBP) and Molecular Function (GOMF), using a p value <0.05. Protein-protein interactions were analysed by 
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String [28]. Gene products previously experimentally detected at the protein level as secreted and/or in extracellular 
region and/or exosome and/or microvesicles were determined according to public available databases (www. 
neXtProt.org, www.exocarta.org, microvesicle.org, geneontology.org, www.proteinatlas.org), and dataset [29]. Gene 
products previously detected at the transcription level in blastocystis or embyonic tissue are listed Tables 1-4 and S2-
according to  microarray datasets and gene expression databases (http://genomewidepdb.proteomix.org or 
https://www.ncbi.nlm.nih.gov/geoprofiles) [30, 16].  The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE  partner repository with the dataset identifier PXD003535 
 
Results 
Proteomic profile of human blastocoel fluid isolated from women aged < and ≥ 37 years 
The aim of the study was to examine the protein composition of human blastocoel fluid isolated from 
blastocysts of women aged <37 years (group A) and women aged ≥ 37 years (group B)  to enlighten differences, at the 
protein level, that can possibly explain blastocyst survival and implantation success known to be very different in the 
two groups. Blastocoel fluid was isolated by micromanipulation, and proteins were identified by a shotgun proteomic 
approach, using label free for the relative quantification of their expression levels. Proteins identified in the control 
(containing only culture medium) and keratins- likely due to a contamination during sample preparation were discarded 
from the analysis (Supplementary Table 1). The proteomic analysis leads to the identification and quantification of 148 
proteins (Fig. 1); 132 and 116 proteins were identified in group A (Supplementary Table 2, average CV 1.2%) and B 
(Supplementary Table 3, average CV 1.3%), respectively (Fig. 1a). Among the 100 proteins commonly expressed in 
both groups, 17 proteins are up-regulated and 44 down-regulated in group B compared to group A (Fig. 1b). These 
proteins are listed in Tables 1 and 2, respectively, while Tables 3 and 4 report the proteins expressed only in A (32) or 
in B (16), respectively. Overall, the analysis identified 33 proteins, which were increased or present only in B while 76 
were decreased in B or present only in A (Fig. 1 As reported in Tables 1-4, Supplementary Table 2 and 3, 98% of the 
differentially regulated proteins and 91 % of the total proteins identified have been previously experimentally detected 
either at the protein level in blastocoel fluid, exosomes, microvesicles or extracellular region or at the gene expression 
level in microarray studies concerning blastocyst transcriptome and gene expression databases. 
Up to now only two papers addressed the issue of the protein content in the blastocoel fluid by a proteomic 
analysis: Jansen et al. [17] described the protein content of the blastocoel together with the medium and the cells, while 
Poli et al. [16], very recently, reported on the proteome of the blastocoel fluid combining the results from shot gun 
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proteomics and gene expression analysis. The present study allows to identify 108 proteins never described before, 
adding unprecedented information on this important human body fluid. 
 
Classification of the differentially expressed proteins based on bioinformatic analysis 
The proteins differentially expressed in the two groups were classified based on Gene Ontology Molecular 
Function and Biological Processes, as shown in Fig. 2. As a further step in the bioinformatic analysis, the proteins were 
manually grouped according to their function taking into account, besides GOMF and GOBP, also keywords and known 
annotations from the literature. It was thus possibile to ascribe each protein to 6 major groups: 1) fertilization and 
embryo implantation, 2) embryo development, 3) nucleic acid interaction, 4) signaling, 5) uncharacterized proteins, 6) 
proteins excluded from the groups listed above categorized as “other” (Fig. 3, Supplementary Table 4). Interestingly, 
comparing the analysis of proteins increased or only expressed in A  (Fig. 3a) with the proteins increased or only 
expressed in B (Fig. 3b), the major differences can be observed in 2 categories: fertilization and embryo implantation 
(12% group A vs 2% group B) and nucleic acid interaction (4% group A vs 13% group B).  
 
Discussion 
According to the promising results obtained by Jensen and collaborators and by Poli and coworkers [16, 17], to 
better delineate possible mechanisms for the effect of maternal ageing on fertility and potential biomarkers for 
evaluating the blastocysts quality and improving pregnancy outcome rate in IVF patients, we examined the proteomic 
profile of blastocoel fluid in woman <37 year old (group A) or ≥37 year old (group B). Comparison between the two 
matched study groups demonstrated, as already known, that pregnancy rate was lower in group B. In this group 4/12 
(33,3%) pregnancies were obtained after frozen- thawed blastocyst transfer cycles versus group A (13/30 pregnancies, 
43,3%). The shotgun proteomic approach allowed identifying 148 proteins, out of which 108 are described for the first 
time in the blastocoel fluid, and 109 are differentially expressed between the two groups. These proteins were 
functionally profiled using a suite of bioinformatics annotation tools and pathway databases, to obtain a comprehensive 
view of the impacted processes, pathways, functions, and networks related to maternal ageing. The bioinformatic 
analysis showed that differential proteins participate in various biological processes, but the main perturbed networks 
refer to fertilization and embryo implantation, as well as to nucleic acid interactions (Fig. 3 and Table S4).  
Interestingly, many of the proteins differentially expressed are related to processes involving ubiquitin, that is 
largely known to play a crucial role in controlling several aspects required to ensure successful pregnancy outcome. In 
particular, the major molecular functions of these proteins consist of histone turnover and transcription factors, crucially 
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required for cell cycle progression and proliferation. Therefore, it is presumed that alterations in their expression level 
could affect implantation potential by altering blastocyst homeostasis towards apoptosis and autophagy settings. The 
following paragraph details the known biological role in reproductive processes of ubiquitin-related proteins which 
have been identified as blastocoel fluid components in the present study and listed in Tables 1-4 and S2-S3. In addition, 
a network showing the known interactions amongst up- or down-regulated ubiquitin-related proteins is shown in Fig.4. 
 In the recent years, increasing observations have demonstrated the role of ubiquitin system in reproductive 
processes, such as gametogenesis, modulation of steroid receptor concentrations, placental development and 
endometrial modification at the beginning of pregnancy [31]. These widerange effects have led to extensive research 
and several studies recently demonstrated the increase of ubiquitylation in the uterus during embryo implantation; thus, 
the proper control and turnover of this key signaling protein activity suggest potential roles in controlling critical 
aspects of implantation [32-35].  This is also emphasized by the observation that ubiquitin is accumulated in trophoblast 
of expanding blastocysts [36], suggesting that dysregulation of ubiquitin system may be responsible for failure IVF 
outcome. In 2009 Katz-Jaffe and collaborators reviewed findings on potential protein biomarkers in the embryo 
secretome [18], identifying a crucial role for ubiquitin. In our study, a huge number of proteins related to ubiquitin 
system has been identified and differentially regulated among the two groups analyzed. The ubiquitinase UBC and 
Ubiquitin Carboxyl-terminal Hydrolase isozyme L1 (UCHL1) are down-regulated in aged blastocysts, as well as 
proteins containing a RING finger domain that plays a key role in the ubiquitination pathway during embryonic 
development [37, 38] such as RING Finger protein 223 (RNF223) and Kelch-like protein 17 (KLHL17). Instead, the 
expression of the 26S Proteasome non-ATPase regulatory subunit 4 (PSMD4), a component of the 26S proteasome 
complex responsible for ubiquitylated proteins degradation, and the AN1-type zinc finger protein 6 (ZFAND6), a 
polyubiquitin binding protein involved in regulating NF-kappaB signaling [39], are completely switched off. 
Interestingly, several differential expressed proteins are substrate of Small Ubiquitin MOdifier (SUMO), which is also 
involved in regulating embryonic viability in mammals [40]. In particular, aged blastocysts lack Ran GTPaseactivating 
protein 1 (RANGAP1), that regulates pathways mainly involved in differentiation, apoptosis and cell cycle by altering 
protein function through changes in activity or cellular localization or by protecting substrates from ubiquitination [41]. 
Instead, they show increased expression of BEN domain-containing protein 4 that belongs to a family of proteins 
involved in histone deubiquitination. Accumulated evidence in the literature has currently demonstrated that the 
monoubiquitylation of histone H2A at lysine 119 is crucially associated with transcriptionally repressed chromatin, as a 
result of the repression activity of Polycomb group proteins [42-46]. The latter proteins are crucial developmental 
regulators that maintain transcriptional repression of hundreds of genes involved in development from early 
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embryogenesis through birth to adulthood [47-50, 37], as well as in signaling or cancer development using chromatin-
based epigenetic mechanisms [51, 52]. In particular, the Polycomb group RING finger protein 1 (PCGF1) acts as key 
cell growth regulator, that promotes cell cycle progression and proliferation by transcriptional repression of the CDK 
cyclin inhibitor p21Waf1/Cip1 [53]. Interestingly, our study reveals that Polycomb group RING finger protein 1 
(PCGF1) has not been detected  in aged blastocysts, providing a further confirmation of the key role of ubiquitylation 
for initiation of pregnancy. Noteworthy, the importance of the crosstalk between Polycomb group proteins and histones 
has been recently demonstrated by the identification of the Jumonji protein JARID2, a component of the histone 
methyltransferase complex that regulates binding of the Polycomb repressive complex 2 to target genes in embryonic 
stem cells [49], as the most represented proteins in the secretome of the preimplantation human embryo able to predict 
positive pregnancy outcome [54]. Moreover, according to a recent observation describing the important role of histone 
H2A variants (H2A.X, H2A.Z and macroH2A) in genome remodeling after fertilization [55] and preimplantation 
embryo development [56], our study reveals that blastocoel fluid of aged woman undergoes a global change in histone 
composition, as it contains soluble histones (H2A.X, H2B and H4) that are completely absent in younger women. 
Noteworthy, any excess of the positively charged histones can allow them to potentially associate non-specifically with 
negatively charged molecules such as DNA in the cell, resulting in deleterious effects on cell viability and genomic 
stability [57]. Indeed, recent studies have highlighted a link between increased soluble H2A.X and apoptosis induction 
[58, 59]. Excessive soluble H2A.X causes chromatin aggregation and inhibition of ongoing gene transcription, but it has 
also non-nucleosomal functions, specifically pro-apoptotic activities. Therefore, to avoid the problems associated with 
excess histone accumulation, most eukaryotic cells largely rely on the strict regulation of their histone protein levels and 
excess histones are degraded by phosphorylation and ubiquitylation-dependent proteolysis [60, 61]. Moreover, a very 
recent report suggests that histones may be targeted for degradation also via the chaperone-mediated autophagy 
pathway in mammalian cells [62]. In keeping with these observations, we identified in blastocoel fluid from aged 
blastocysts an increased amount of Ubiquilin-2 (UBQLN2), which is involved in regulation of different protein 
degradation mechanisms and pathways including ubiquitin-proteasome system and autophagy, a survival mechanism 
whose deregulation has been linked to non-apoptotic cell death through inducing cell cycle arrest [63, 64]. Noteworthy, 
increased autophagy of aged blastocysts is further confirmed by absence in the blastocoel fluid of Laminin subunit 
gamma-1 (LAMC1), which is crucially involved in protection from autophagy [65, 66]. 
 Besides ubiquitin, our proteomic data reveals that also FAAH2, a key protein in the endocannabinoid system, 
is differentially expressed in young and aged women blastocoel fluid.  Recently, comprehensive studies have indicated 
that endocannabinoids, a group of bioactive lipids including anandamide (AEA), are actively involved in the process of 
11 
 
reproduction and pregnancy, from gametogenesis, uterine receptivity, early embryo-blastocyst development, oviductal 
transport and implantation through to birth [67-69]. As a consequence of its potential physiological impact, 
endocannabinoid signaling is finely regulated at multiple levels through several metabolic routes, including the main 
degradative enzyme fatty acid amide hydrolase (FAAH), that cleaves and inactivates AEA [70]. Changes in the activity 
and/or expression of FAAH determine significant fluctuations in AEA levels, which in turn can lead to success or 
failure of pregnancy [71]. In line with this, it has been reported that women in an IVF program who have successful 
implantation, have low serum AEA levels associated with elevated levels of in their peripheral lymphocytes at 6 weeks 
gestation, whereas low FAAH [72, 73] and high AEA levels in blood are associated with spontaneous threatened 
miscarriage [74]. In keeping with these observations, our data revealed that lower levels of FAAH2, an isoform highly 
expressed in higher placental mammals [75] in the blastocoel fluid of aged woman. Given the potential impact of this 
observation, additional studies will be devoted to validate this preliminary result.  
In summary, by applying a proteomic approach to compare blastocoel fluid from <37 years old and ≥37 year 
old women blastocysts, we suggest that increased rate of implantation failure in aged IVF patients relies on the pro-
apoptotic signature of their blastocysts, as a consequence of the dramatic dysregulation of mechanisms involved in the 
regulation of ubiquitin system as well as, potentially, in the control of a correct AEA tone. Noteworthy, several 
additional proteins not related to the ubiquitin system but equally involved in apoptotic processes have been found 
differentially regulated among the two groups, such as the Isoform 2 of Protein BEX3 (NGFRAP1) [76], Dermicin 
(DCD) [77], the Isoform 3 of Proline-rich AKT1 substrate 1 (AKT1S1) [78], Calmodulin (CALM) [79] and the 
eukaryotic translation elongation factor 1A (EEF1A) [80, 81], providing a further confirmation of the pro-apoptotic 
signature of aged blastocysts. 
In conclusion the results of our deep proteomic investigation provides valuable information on the molecular 
player involved in biological processes related to blastocyst features in aged women which, in turn, can be used as a 
starting point towards the identification of non-invasive tools to investigate and ameliorate blastocyst viability, and 
improving clinical outcome of IVF cycles. 
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Figure Legends 
Fig. 1 Proteomic profile of human blastocoel fluid isolated from women aged < (group A) and ≥ (group B) 37 
years. a Venn diagram of the proteins identified in group A and B. b Vulcano plot showing the proteins common to 
both groups differentially expressed in group B compared to group A. Common proteins were considered differentially 
expressed if they showed significant t-test difference (cut-off at 5% permutation-based False Discovery Rate) between 
the two groups. Proteins up and down regulated are indicated in black and dark grey, respectively. Proteins which are 
present at levels not statistically different between groups A and B are indicated in light grey below the horizontal 
threshold line 
 
Fig. 2 Classification of the proteins differentially expressed based on GOMF and GOBP. The proteins 
differentially expressed in A and B groups were classified based on molecular function (GOMF) and biological 
processes (GOBP) a Classification of proteins down regulated in B or present only in A. b Classification of proteins up 
regulated or present only in B. 
 
Fig. 3  Functional analysis of the proteins differentially expressed in A and B. The proteins were manually grouped 
according to their function in biological processes taking into account, besides GOMF, and GOBP, also keywords and 
annotations known from literature (Supplementary Table 4). a Classification of proteins down regulated in B or present 
only in A. b Classification of proteins up regulated or present only in B. 
 
Fig. 4 Protein-protein interaction analysis of the proteins differentially expressed in A and B involved in the 
ubiquitin system. The analysis was performed by STRING. Stronger associations are represented by thicker lines.  
Proteins increased or decreased in B are indicated by an arrow. PSMD8, PSMD4, PSMD2, PSMD14 are isoforms of 
PSMD4 which was found decreased in B. 
 
Table S1: List of proteins discarted from the analysis. Proteins identified in the control (containing only 
culture medium) and keratins likely due to a contamination during sample preparation, were discarded 
from the analysis.  
Medium/Keratin 
Protein IDs Protein names Gene names 
P04217 Alpha-1B-glycoprotein A1BG 
P43652 Afamin AFM 
C9JV77 Alpha-2-HS-glycoprotein AHSG 
P02768 Serum albumin ALB 
P25311 Zinc-alpha-2-glycoprotein AZGP1 
Q6ISB3 Grainyhead-like protein 2 homolog GRHL2 
P69905 Hemoglobin subunit alpha HBA1 
P00738 Haptoglobin HP 
P02790 Hemopexin HPX 
P01876 Ig alpha-1 chain C region IGHA1 
P04264 Keratin, type II cytoskeletal 1 KRT1 
P13645 Keratin, type I cytoskeletal 10 KRT10 
P02533 Keratin, type I cytoskeletal 14 KRT14 
P08779 Keratin, type I cytoskeletal 16 KRT16 
Q04695 Keratin, type I cytoskeletal 17 KRT17 
P35908 Keratin, type II cytoskeletal 2 epidermal KRT2 
P13647 Keratin, type II cytoskeletal 5 KRT5 
P02538 Keratin, type II cytoskeletal 6A;Keratin, type II cytoskeletal 6C KRT6A;KRT6C 
Q7Z794 Keratin, type II cytoskeletal 1b KRT77 
Q8N1N4 Keratin, type II cytoskeletal 78 KRT78 
Q9NSB4 Keratin, type II cuticular Hb2 KRT82 
P35527 Keratin, type I cytoskeletal 9 KRT9 
F8WCG0 Myotubularin-related protein 14 MTMR14 
P02763 Alpha-1-acid glycoprotein 1 ORM1 
A6NNF7 Amiloride-sensitive sodium channel subunit delta SCNN1D 
C9JNR7 Septin-10 SEPT10 
P02787 Serotransferrin TF 
P02766 Transthyretin TTR 
E7EQ64 Trypsin-1;Alpha-trypsin chain 1;Alpha-trypsin chain 2 PRSS1 
 
Table S2: List of proteins identified in group A by a shotgun approach. Previous identification: in the Table 
the proteins previously identified in human blastocoel fluid (16, 17) are indicated with a capital X, while x 
indicates gene products previously experimentally detected at the protein level as secreted and/or present 
in extracellular region and/or in exosome and/or in microvesicles according to public available databases 
and dataset (www.neXtProt.org, www.exocarta.org, microvesicle.org, geneontology.org, 
www.proteinatlas.org, 29) or at the gene expression level from microarray data (16, 92) or at the 
transcription level in blastocystis or embyonic  tissue according to http://genomewidepdb.proteomix.org or 
https://www.ncbi.nlm.nih.gov/geoprofiles databases. The table lists only the proteins present and 
quantified in at least 3 out of 5 technical repeats using a false positive rate of 0.05 and minimum peptide 
length 9 amino acids, reporting in a column the proteins identified with FDR 0.01. 
 
Protein 
IDs 
Protein names Gene names PEP Razor + 
unique 
peptides 
FDR 
1% 
Previous 
identification  
P12273 Prolactin-inducible protein PIP 5.24E-06 2 X X 
Q8NBJ4 Golgi membrane protein 1 GOLM1 0.018711 1 X x 
P01040 Cystatin-A CSTA 1.22E-08 2 X X 
P20382 Pro-MCH;Neuropeptide-glycine-glutamic 
acid; 
PMCH 0.002462 1 X x 
Q8TE76 MORC family CW-type zinc finger protein 
4 
MORC4 0.018241 1 X x 
Q8TE56 A disintegrin and metalloproteinase with 
thrombospondin motifs 17 
ADAMTS17 0.022011 1 X x 
D6R956 Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 
UCHL1 0.004585 1  X 
O95202 LETM1 and EF-hand domain-containing 
protein 1, mitochondrial 
LETM1 0.028673 1  x 
Q9UGM3 Deleted in malignant brain tumors 1 
protein 
DMBT1 0.006933 1 X X 
P31025 Lipocalin-1;Putative lipocalin 1-like 
protein 1 
LCN1;LCN1P1 1.85E-55 2 X X 
Q6UWP8 Suprabasin SBSN 0.000208 1 X X 
Q9BR77 Coiled-coil domain-containing protein 77 CCDC77 0.009722 1 X x 
Q96RW7 Hemicentin-1 HMCN1 0.024825 1 X x 
P31151 Protein S100-A7;Protein S100-A7A S100A7;S100A7A 3.14E-51 4 X X 
H0Y7A7 Calmodulin CALM2;CALM1 0.005618 1 X x 
Q6GMR7 Fatty-acid amide hydrolase 2 FAAH2 0.02707 1 X x 
P19021 Peptidyl-glycine alpha-amidating 
monooxygenase; 
PAM 0.029696 1  x 
O94788-3 Retinal dehydrogenase 2 ALDH1A2 0.026311 1  x 
Q5VW26 Nuclear factor 1;Nuclear factor 1 B-type NFIB 0.01383 1  x 
Q9BV73 Centrosome-associated protein CEP250 CEP250 0.025154 1  X 
Q9NZT1 Calmodulin-like protein 5 CALML5 8E-153 4 X X 
P81605 Dermcidin;Survival-promoting 
peptide;DCD-1 
DCD 4.24E-08 2 X X 
Q6PGQ7 Protein aurora borealis BORA;FLJ22624 0.03061 1 X x 
C9K0L2 Maestro heat-like repeat-containing protein 
family member 7 
HEATR8 0.030121 1 X x 
P61626 Lysozyme C LYZ 2.78E-23 1 X X 
Q8N8E3 Centrosomal protein of 112 kDa CEP112 0.008359 1 X x 
Q9BY89 Uncharacterized protein KIAA1671 KIAA1671 0.012704 1  x 
Q96F24 Nuclear receptor-binding factor 2 NRBF2 0.005732 1 X x 
E7ERA6 RING finger protein 223 RNF223 0.028835 1 X  
F8W8U3 Homeobox protein Meis1 MEIS1 0.031584 1  x 
P0CG48 Polyubiquitin-C;Ubiquitin;Polyubiquitin-B UBC;UBB 0.001463 1 X X 
Q6JVE6 Epididymal-specific lipocalin-10 LCN10 0.027122 1  x 
Q9HCJ0 Trinucleotide repeat-containing gene 6C 
protein 
TNRC6C 0.02214 1 X x 
F8W878 Brain-specific angiogenesis inhibitor 1-
associated protein 2 
BAIAP2 0.018041 1 X x 
P05109 Protein S100-A8 S100A8 3.51E-69 2 X X 
Q13635-4 Isoform S of Protein patched homolog 1 PTCH1 0.0054 1 X x 
Q8NBP5 Major facilitator superfamily domain-
containing protein 9 
MFSD9 0.024966 1 X x 
F8WCM5 Insulin;Insulin B chain;Insulin A chain INS-IGF2;INS 6.49E-07 1 X X 
G8JLG2 Corneodesmosin CDSN 0.018446 1  X 
P01566 Interferon alpha-10;Interferon alpha-21; IFNA10;IFNA21 0.03168 1 X x 
P22732 Solute carrier family 2, facilitated glucose 
transporter member 5 
SLC2A5 0.028098 1  x 
Q8TAL5 Uncharacterized protein C9orf43 C9orf43 0.028085 1  x 
J3KNN1 Polypeptide N-
acetylgalactosaminyltransferase 9 
GALNT9 0.024813 1 X  
Q02413 Desmoglein-1 DSG1 2.58E-31 2 X X 
P14923 Junction plakoglobin JUP 5.14E-15 2 X X 
Q8NI35-5 Isoform 5 of InaD-like protein INADL 0.018277 1  x 
G3V314 Ena/VASP-like protein EVL 0.03031 1  x 
Q12972-3 Isoform Gamma of Nuclear inhibitor of 
protein phosphatase 1 
PPP1R8 0.031102 1  x 
Q9HCE0 Ectopic P granules protein 5 homolog EPG5 0.030831 1  x 
Q76G19 PDZ domain-containing protein 4 PDZD4 5.95E-15 2 X x 
Q5T749 Keratinocyte proline-rich protein KPRP 5.50E-12 5 X X 
H3BUN7 SH2B adapter protein 1 SH2B1 0.017553 1 X x 
H0YNB0 Unconventional myosin-Ie MYO1E 0.022468 1  x 
J3KMZ5 Serotonin N-acetyltransferase AANAT 0.014783 1  x 
P28290 Sperm-specific antigen 2 SSFA2 0.015064 1 X x 
Q6ZU67 BEN domain-containing protein 4 BEND4 0.029939 1  x 
Q9H1N7 Adenosine 3-phospho 5-phosphosulfate 
transporter 2 
SLC35B3 0.023363 1  x 
P05060 Secretogranin-1;GAWK peptide;CCB 
peptide 
CHGB 0.023689 1 X x 
Q9NZL9-5 Isoform 5 of Methionine 
adenosyltransferase 2 subunit beta 
MAT2B 0.02745 1  x 
Q9UHD9 Ubiquilin-2 UBQLN2 0.02898 1 X x 
Q96NH3-4 Protein broad-minded BROMI;C6orf170 0.011429 1 X x 
P46060 Ran GTPase-activating protein 1 RANGAP1 0.020731 1  x 
Q9H1K1-2 Isoform 2 of Iron-sulfur cluster assembly 
enzyme ISCU, mitochondrial 
ISCU 0.029122 1  x 
P04745 Alpha-amylase 1;Pancreatic alpha-amylase AMY1A;AMY2A 0.016273 1  X 
B4DIP4 Eukaryotic translation initiation factor 2-
alpha kinase 1 
EIF2AK1 0.024445 1  x 
Q9NYL2- Isoform 2 of Mitogen-activated protein ZAK 0.010561 1  x 
2 kinase kinase kinase MLT 
B4DYB5 cDNA FLJ53372 SPAG16 0.025535 1   
B7Z8Z7 RNA-binding protein 47 RBM47 0.02829 1  x 
F5H1U9 Multiple PDZ domain protein MPDZ 0.03135 1 X x 
P06454 Prothymosin alpha;Thymosin alpha-1 PTMA 0.001343 1 X X 
C9JH18 PERQ amino acid-rich with GYF domain-
containing protein 2 
GIGYF2 0.000158 2  x 
C9JNL6 Electrogenic sodium bicarbonate 
cotransporter 4 
SLC4A5 0.014409 1  x 
C9JSC0 POU domain, class 6, transcription factor 2 POU6F2 0.029639 1  x 
Q96BQ5 Coiled-coil domain-containing protein 127 CCDC127 0.031674 1 X x 
Q9NQ38 Serine protease inhibitor Kazal-type 5 SPINK5 0.001557 1 X x 
E7ENK3 Glutamate receptor, ionotropic kainate 1 GRIK1 0.027858 1  x 
Q13201 Multimerin-1;Platelet glycoprotein Ia*;155 
kDa platelet multimerin 
MMRN1 0.024454 1 X x 
P02788 Lactotransferrin;Kaliocin-1;Lactoferroxin-
A;Lactoferroxin-B;Lactoferroxin-C 
LTF 0.004647 1 X X 
P04406 Glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH 2.45E-07 3 X X 
P11532 Dystrophin DMD 0.015725 1  x 
E9PQB1 Serine/arginine repetitive matrix protein 5 SRRM5 0.015627 1 X x 
Q9UKR0 Kallikrein-12 KLK12 0.02885 1  x 
F8WAU4 Elongation factor G, mitochondrial GFM1 0.014496 1 X x 
F8WCP6 Kinesin-like protein KIF21A KIF21A 0.029222 1  x 
Q9P0W5-4 Schwannomin-interacting protein 1 SCHIP1 0.028326 1  x 
H0Y3B9 BTB/POZ domain-containing protein 
KCTD2 
KCTD2 0.027761 1 X x 
H0Y7H7 Dedicator of cytokinesis protein 4 DOCK4 0.030214 1  x 
Q13535 Serine/threonine-protein kinase ATR ATR 0.024667 1  x 
Q6FIF0 AN1-type zinc finger protein 6 ZFAND6 0.030174 1  x 
P14618 Pyruvate kinase isozymes 
M1/M2;Pyruvate kinase 
PKM2 0.000118 2 X X 
J9JIC5 Protein Njmu-R1 C17orf75 0.031192 1 X x 
Q96DH6 RNA-binding protein Musashi homolog 2 MSI2 0.007825 1  x 
K7EKM7 Small integral membrane protein 24 SMIM24 0.009651 1 X x 
M0QXR7 Leucine-rich repeat-containing protein 63 LRRC63 0.020219 1   
O00555 Voltage-dependent P/Q-type calcium 
channel subunit alpha-1A 
CACNA1A 0.000283 2 X x 
O60320-2 Isoform 2 of Protein FAM189A1 FAM189A1 0.012422 1  x 
O75556 Mammaglobin-B SCGB2A1 0.030478 1  x 
O76042 Putative uncharacterized protein C3orf51 C3orf51 0.01043 1 X  
P05089 Arginase-1 ARG1 0.000272 2 X X 
P06702 Protein S100-A9 S100A9 8.91E-09 3 X X 
P06733 Alpha-enolase ENO1 2.54E-06 2  X 
P11047 Laminin subunit gamma-1 LAMC1 0.029392 1  x 
P15924 Desmoplakin DSP 3.07E-21 7 X X 
P31944 Caspase-14;Caspase-14 subunit 
p19;Caspase-14 subunit p10 
CASP14 3.99E-26 4 X X 
P51843 Nuclear receptor subfamily 0 group B 
member 1 
NR0B1 0.013215 1  x 
P52740 Zinc finger protein 132 ZNF132 0.002584 1 X x 
Q5VWC4 26S proteasome non-ATPase regulatory 
subunit 4 
PSMD4 0.031718 1  x 
Q00994-2 Isoform 2 of Protein BEX3 NGFRAP1 0.008688 1  x 
Q01469 Fatty acid-binding protein, epidermal FABP5 1.08E-24 2 X X 
Q08188 Protein-glutamine gamma-
glutamyltransferase E; 
TGM3 0.011907 1  X 
Q08554 Desmocollin-1 DSC1 2.80E-06 3 X X 
Q12778 Forkhead box protein O1 FOXO1 0.007693 1  x 
Q13164-4 Mitogen-activated protein kinase 7 MAPK7 0.027772 1 X x 
Q13422-4 DNA-binding protein Ikaros IKZF1 0.021892 1   
Q13542 Eukaryotic translation initiation factor 4E-
binding protein 2 
EIF4EBP2 0.020583 1 X x 
Q14764 Major vault protein MVP 1.25E-07 4 X X 
Q3SYA6 MAGEC3 protein MAGEC3 0.027463 1   
Q5D862 Filaggrin-2 FLG2 0.000426 2 X X 
Q5GH76 XK-related protein 4 XKR4 0.008783 1 X  
Q5HYA8 Meckelin TMEM67 0.010896 1  x 
Q5HYK7 SH3 domain-containing protein 19 SH3D19 0.012887 1 X x 
Q5T2D2 Trem-like transcript 2 protein TREML2 0.025847 1  x 
Q5T750 Skin-specific protein 32 XP32 0.016572 1  X 
Q5TA76 Late cornified envelope protein 3A LCE3A 0.024214 1   
Q6TDP4 Kelch-like protein 17 KLHL17 0.024283 1  x 
Q9UJQ4 Sal-like protein 4 SALL4 0.024516 1  x 
Q86YZ3 Hornerin HRNR 3.22E-10 2 X X 
Q8N139 ATP-binding cassette sub-family A 
member 6 
ABCA6 0.014869 1 X x 
Q96B36-3 Isoform 3 of Proline-rich AKT1 substrate  AKT1S1 0.028634 1  x 
Q9BSM1 Polycomb group RING finger protein 1 PCGF1 0.023367 1 X x 
Q9BTT4 Mediator of RNA polymerase II 
transcription subunit 10 
MED10 0.003212 1 X x 
Q9H3U1 Protein unc-45 homolog A UNC45A 0.011958 1  x 
 
Table S3: List of proteins identified in group B by a shotgun approach. Previous identification: in the Table 
the proteins previously identified in human blastocoel fluid (16, 17) are indicated with a capital X, while x 
indicates gene products previously experimentally detected at the protein level as secreted and/or present 
in extracellular region and/or in exosome and/or in microvesicles according to public available databases 
and dataset (www.neXtProt.org, www.exocarta.org, microvesicle.org, geneontology.org, 
www.proteinatlas.org, 29) or at the gene expression level from microarray data (16, 92) or at the 
transcription level in blastocystis or embyonic tissue according to http://genomewidepdb.proteomix.org or 
https://www.ncbi.nlm.nih.gov/geoprofiles databases.  The table lists only the proteins present and 
quantified in at least 3 out of 5 technical repeats using a false positive rate of 0.05 and minimum peptide 
length 9 amino acids, reporting in a column the proteins identified with FDR 0.01. 
 
Protein 
IDs 
Protein names Gene names PEP Razor + 
unique 
peptides 
FDR 
1% 
Previous 
identification 
P12273 Prolactin-inducible protein PIP 5.24E-06 2 X X 
Q8NBJ4 Golgi membrane protein 1 GOLM1 0.018711 1 X x 
P01040 Cystatin-A CSTA 1.22E-08 2 X X 
P20382 Pro-MCH;Neuropeptide-glycine-
glutamic acid 
PMCH 0.002462 1 X x 
Q8TE76 MORC family CW-type zinc 
finger protein 4 
MORC4 0.018241 1 X x 
Q8TE56 A disintegrin and 
metalloproteinase with 
thrombospondin motifs 17 
ADAMTS17 0.022011 1 X x 
D6R956 Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 
UCHL1 0.004585 1  X 
O95202 LETM1 and EF-hand domain-
containing protein 1, 
mitochondrial 
LETM1 0.028673 1  x 
Q9UGM3 Deleted in malignant brain 
tumors 1 protein 
DMBT1 0.006933 1 X X 
P31025 Lipocalin-1;Putative lipocalin 1-
like protein 1 
LCN1;LCN1P1 1.85E-55 2 X X 
Q6UWP8 Suprabasin SBSN 0.000208 1 X X 
Q9BR77 Coiled-coil domain-containing 
protein 77 
CCDC77 0.009722 1 X x 
Q96RW7 Hemicentin-1 HMCN1 0.024825 1 X x 
P31151 Protein S100-A7;Protein S100-
A7A 
S100A7;S100A7A 3.14E-51 4 X X 
H0Y7A7 Calmodulin CALM2;CALM1 0.005618 1 X x 
Q6GMR7 Fatty-acid amide hydrolase 2 FAAH2 0.02707 1 X x 
P19021 Peptidyl-glycine alpha-amidating 
monooxygenase 
PAM 0.029696 1  x 
O94788-3 Isoform 3 of Retinal 
dehydrogenase 2 
ALDH1A2 0.026311 1 X x 
Q5VW26 Nuclear factor 1;Nuclear factor 1 
B-type 
NFIB 0.01383 1  x 
Q9BV73 Centrosome-associated protein 
CEP250 
CEP250 0.025154 1  X 
Q9NZT1 Calmodulin-like protein 5 CALML5 8E-153 4 X X 
P81605 Dermcidin;Survival-promoting DCD 4.24E-08 2 X X 
peptide;DCD-1 
Q6PGQ7 Protein aurora borealis BORA;FLJ22624 0.03061 1 X x 
C9K0L2 Maestro heat-like repeat-
containing protein family 
member 7 
HEATR8 0.030121 1 X  
P61626 Lysozyme C LYZ 2.78E-23 1 X X 
Q8N8E3 Centrosomal protein of 112 kDa CEP112 0.008359 1 X  
Q9BY89 Uncharacterized protein  KIAA1671 0.012704 1  x 
Q96F24-2 Nuclear receptor-binding factor 2 NRBF2 0.005732 1 X x 
E7ERA6 RING finger protein 223 RNF223 0.028835 1 X  
F8W8U3 Homeobox protein Meis1 MEIS1 0.031584 1  x 
P0CG48 Polyubiquitin-
C;Ubiquitin;Polyubiquitin-B 
UBC;UBB 0.001463 1 X X 
Q6JVE6 Epididymal-specific lipocalin-10 LCN10 0.027122 1  x 
Q9HCJ0 Trinucleotide repeat-containing 
gene 6C protein 
TNRC6C 0.02214 1 X x 
F8W878 Brain-specific angiogenesis 
inhibitor 1-associated protein 2 
BAIAP2 0.018041 1 X x 
P05109 Protein S100-A8 S100A8 3.51E-69 2 X X 
Q13635-4 Isoform S of Protein patched 
homolog 1 
PTCH1 0.0054 1 X x 
Q8NBP5 Major facilitator superfamily 
domain-containing protein 9 
MFSD9 0.024966 1 X x 
F8WCM5 Insulin;Insulin B chain;Insulin A 
chain 
INS-IGF2;INS 6.49E-07 1 X X 
G8JLG2 Corneodesmosin CDSN 0.018446 1  X 
P01566 Interferon alpha-10;Interferon 
alpha-21 
IFNA10;IFNA21 0.03168 1 X x 
P22732 Solute carrier family 2, facilitated 
glucose transporter member 5 
SLC2A5 0.028098 1  x 
Q8TAL5 Uncharacterized protein C9orf43 C9orf43 0.028085 1  x 
J3KNN1 Polypeptide N-
acetylgalactosaminyltransferase 9 
GALNT9 0.024813 1 X  
Q02413 Desmoglein-1 DSG1 2.58E-31 2 X X 
Q8NI35-5 Isoform 5 of InaD-like protein INADL 0.018277 1  x 
G3V314 Ena/VASP-like protein EVL 0.03031 1  x 
Q12972-3 Isoform Gamma of Nuclear 
inhibitor of protein phosphatase 1 
PPP1R8 0.031102 1  x 
Q9HCE0 Ectopic P granules protein 5 
homolog 
EPG5 0.030831 1  x 
Q76G19 PDZ domain-containing protein 4 PDZD4 5.95E-15 2 X x 
Q5T749 Keratinocyte proline-rich protein KPRP 5.50E-12 5 X X 
H3BUN7 SH2B adapter protein 1 SH2B1 0.017553 1 X x 
H0YNB0 Unconventional myosin-Ie MYO1E 0.022468 1  x 
J3KMZ5 Serotonin N-acetyltransferase AANAT 0.014783 1  x 
P28290 Sperm-specific antigen 2 SSFA2 0.015064 1 X x 
Q6ZU67 BEN domain-containing protein 
4 
BEND4 0.029939 1  x 
Q9H1N7 Adenosine 3-phospho 5-
phosphosulfate transporter 2 
SLC35B3 0.023363 1  x 
P05060 Secretogranin-1;GAWK 
peptide;CCB peptide 
CHGB 0.023689 1 X x 
Q9NZL9-5 Isoform 5 of Methionine 
adenosyltransferase 2 subunit 
beta 
MAT2B 0.02745 1  x 
Q9UHD9 Ubiquilin-2 UBQLN2 0.02898 1 X x 
Q96NH3 Protein broad-minded BROMI;C6orf170 0.011429 1 X x 
A6NKX1 Putative uncharacterized protein 
CXorf52B 
NCRNA00204 0.028229 1 X  
B4DR52 Histone H2B;Histone H2B type 
1-K 
HIST2H2BF;HIST1H2BK 4.95E-25 1 X X 
B4DYB5 cDNA FLJ53372 SPAG16 0.025535 1   
B7Z8Z7 RNA-binding protein 47 RBM47 0.02829 1  x 
P06454 Prothymosin alpha;Thymosin 
alpha-1 
PTMA 0.001343 1 X X 
Q9UJ42 Probable G-protein coupled 
receptor 160 
GPR160 0.009327 1 X x 
C9JH18 PERQ amino acid-rich with GYF 
domain-containing protein 2 
GIGYF2 0.000158 2  x 
C9JSC0 POU domain, class 6, 
transcription factor 2 
POU6F2 0.029639 1  x 
Q96BQ5 Coiled-coil domain-containing 
protein 127 
CCDC127 0.031674 1 X x 
E7ENK3 Glutamate receptor, ionotropic 
kainate 1 
GRIK1 0.027858 1  x 
Q13201 Multimerin-1;Platelet 
glycoprotein Ia*;155 kDa platelet 
multimerin 
MMRN1 0.024454 1 X x 
P04406 Glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH 2.45E-07 3 X X 
P11532 Dystrophin DMD 0.015725 1  x 
E9PQB1 Serine/arginine repetitive matrix 
protein 5 
SRRM5 0.015627 1 X x 
Q96DR8 Mucin-like protein 1 MUCL1 0.010421 1 X X 
F8WAU4 Elongation factor G, 
mitochondrial 
GFM1 0.014496 1 X x 
Q9P0W5-4 Schwannomin-interacting protein 
1 
SCHIP1 0.028326 1  x 
H0Y3T1 Protein CROC-4 C1orf61 0.031572 1  x 
P14618 Pyruvate kinase isozymes 
M1/M2;Pyruvate kinase 
PKM2 0.000118 2 X X 
Q96ST8 Centrosomal protein of 89 kDa CEP89 0.03077 1  x 
K7EKM7 Small integral membrane protein 
24 
SMIM24 0.009651 1 X x 
M0QXR7 Leucine-rich repeat-containing 
protein 63 
LRRC63 0.020219 1   
O00555 Voltage-dependent P/Q-type 
calcium channel subunit alpha-
1A 
CACNA1A 0.000283 2 X  
O75553-5 Disabled homolog 1 DAB1 0.029822 1  x 
O75665 Oral-facial-digital syndrome 1 
protein 
OFD1 0.000409 2  x 
P16104 Histone H2A.x;Histone H2A 
type 1-A 
H2AFX;HIST1H2AA 1.95E-29 2 X X 
P05089 Arginase-1 ARG1 0.000272 2 X X 
P06702 Protein S100-A9 S100A9 8.91E-09 3 X X 
P06733 Alpha-enolase ENO1 2.54E-06 2 X X 
P14923 Junction plakoglobin JUP 5.14E-15 2 X X 
P15924 Desmoplakin DSP 3.07E-21 7 X X 
P31944 Caspase-14;Caspase-14 subunit 
p19;Caspase-14 subunit p10 
CASP14 3.99E-26 4 X X 
P48431 Transcription factor SOX-2 SOX2 0.027433 1 X x 
P51654 Glypican-3;Secreted glypican-3 GPC3 0.031467 1  x 
P52740 Zinc finger protein 132 ZNF132 0.002584 1 X x 
P62805 Histone H4 HIST1H4A 0.006819 1 X X 
Q05639 Elongation factor 1-alpha 
2;Elongation factor 1-alpha 1; 
EEF1A2;EEF1A1 0.000444 1 X X 
Q01469 Fatty acid-binding protein, 
epidermal 
FABP5 1.08E-24 2 X X 
Q08188 Protein-glutamine gamma-
glutamyltransferase E; 
TGM3 0.011907 1  X 
Q08554 Desmocollin-1 DSC1 2.80E-06 3 X X 
Q12778 Forkhead box protein O1 FOXO1 0.007693 1  x 
Q13164-4 Mitogen-activated protein kinase 
7 
MAPK7 0.027772 1 X x 
Q13422-4 DNA-binding protein Ikaros IKZF1 0.021892 1   
Q14764 Major vault protein MVP 1.25E-07 4 X X 
Q15147 1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
beta-4 
PLCB4 1.58E-19 2  x 
Q5D862 Filaggrin-2 FLG2 0.000426 2  X 
Q5HYA8 Meckelin TMEM67 0.010896 1  x 
Q5HYK7 SH3 domain-containing protein 
19 
SH3D19 0.012887 1 X x 
Q5J5C9 Beta-defensin 121 DEFB121 0.031279 1  x 
Q5T750 Skin-specific protein 32 XP32 0.016572 1  X 
Q5TA76 Late cornified envelope protein 
3A 
LCE3A 0.024214 1   
Q9UJQ4 Sal-like protein 4 SALL4 0.024516 1  x 
Q86YZ3 Hornerin HRNR 3.22E-10 2 X X 
Q8N139 ATP-binding cassette sub-family 
A member 6 
ABCA6 0.014869 1 X x 
Q9BTT4 Mediator of RNA polymerase II 
transcription subunit 10 
MED10 0.003212 1 X x 
Q9H6A9 Pecanex-like protein 3 PCNXL3 0.018665 1  x 
 
 Table S4: Functional analysis of differentially expressed proteins. The proteins were manually grouped according to their function in biological processes 
taking into account, besides GOMF, GOBP and GOCC, also keywords and annotations known from the literature. It was therefore possible to ascribe each 
protein to 6 major groups: 1) fertilization and embryo implantation, 2) embryo development, 3) nucleic acid interaction, 4) signaling, 5) uncharacterized 
proteins. Proteins excluded from the groups listed above were categorized as “other”. The table lists only the proteins present and quantified in at least 3 
out of 5 technical repeats using a false positive rate of 0.05 and minimum peptide length 9 amino acids, reporting bold the proteins identified with FDR 0.01. 
 Under expressed in B or present only in A  Over expressed or present only in B 
   Gene Name Protein name   Gene name  Protein name 
Fertilization, 
Embryo pre-
implantation, 
Implantation 
only A C17orf75 Protein Njmu-R1   only B DEFB121 Beta-defensin 121 
 only A KLK12 Kallikrein-12      
 only A LAMC1 Laminin subunit gamma-1      
 only A PSMD4 26S proteasome non-ATPase regulatory 
subunit 4 
     
  only A RANGAP1 Ran GTPase-activating protein 1      
   FAAH2 Fatty-acid amide hydrolase 2      
   CALM2;CALM1 Calmodulin      
   UCHL1 Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 
     
    CSTA Cystatin-A         
          
Embryo 
development  
only A AMY1A;AMY2A… Alpha-amylase 1;Pancreatic alpha-
amylase;Alpha-amylase 2B 
  only B DAB1 Isoform DAB553 of Disabled homolog 1 
  only A ATR Serine/threonine-protein kinase ATR  only B OFD1 Oral-facial-digital syndrome 1 protein 
  only A KIF21A Kinesin-like protein KIF21A     
  only A LTF Lactotransferrin;Kaliocin-1;Lactoferroxin-
A;Lactoferroxin-B;Lactoferroxin-C 
 only B SOX2 Transcription factor SOX-2 
  only A MSI2 RNA-binding protein Musashi homolog 2  only B GPC3 Glypican-3;Secreted glypican-3 
  only A NR0B1 Nuclear receptor subfamily 0 group B 
member 1 
 only B MUCL1 Mucin-like protein 1 
  only A SLC4A5 Electrogenic sodium bicarbonate 
cotransporter 4 
 only B CEP89 Centrosomal protein of 89 kDa 
  only A UNC45A Protein unc-45 homolog A   BROMI;C6orf170 Protein broad-minded 
   DSG1 Desmoglein-1   UBQLN2 Ubiquilin-2 
   GALNT9 Polypeptide N-
acetylgalactosaminyltransferase 9 
  MYO1E Unconventional myosin-Ie  
   SLC2A5 Solute carrier family 2, facilitated glucose 
transporter member 5 
  EVL Ena/VASP-like protein 
   CDSN Corneodesmosin   JUP Junction plakoglobin  
   INS-IGF2;INS Insulin;Insulin B chain;Insulin A chain      
   S100A8 Protein S100-A8      
   BAIAP2 Brain-specific angiogenesis inhibitor 1-
associated protein 2 
     
   TNRC6C Trinucleotide repeat-containing gene 6C 
protein 
     
   MEIS1 Homeobox protein Meis1      
   BORA;FLJ22624 Protein aurora borealis      
   CEP250 Centrosome-associated protein CEP250      
   ALDH1A2 Isoform 3 of Retinal dehydrogenase 2      
   PAM Peptidyl-glycine alpha-amidating 
monooxygenase.... 
     
   PRSS1 Trypsin-1;Alpha-trypsin chain 1;Alpha-
trypsin chain 2 
     
   HMCN1 Hemicentin-1      
   SBSN Suprabasin      
   LCN1;LCN1P1 Lipocalin-1;Putative lipocalin 1-like 
protein 1 
     
   DMBT1 Deleted in malignant brain tumors 1 
protein 
     
    PMCH Pro-MCH;Neuropeptide-glycine-glutamic 
acid... 
        
          
Nucleic Acid 
interaction 
only A PCGF1 Polycomb group RING finger protein 1   only B H2AFX;HIST1H2AA;HIST1H2AB.... Histone H2A.x;Histone H2A type 1-A;Histone 
H2A type 1-B/E;Histone H2A type 1........ 
   NRBF2 Nuclear receptor-binding factor 2  only B HIST1H4A Histone H4 
   NFIB Nuclear factor 1;Nuclear factor 1 B-type  only B EEF1A2;EEF1A1;EEF1A1P5 Elongation factor 1-alpha 2;Elongation factor 1-
alpha 1;Putative elongation factor 1-alpha-like 3 
      only B HIST2H2BF;HIST1H2BK.... Histone H2B;Histone H2B type 1-K;Histone H2B 
type 1-J;Histone H2B type 1-O..... 
            BEND4 BEN domain-containing protein 4 
           
Signalling only A DOCK4 Dedicator of cytokinesis protein 4   only B PLCB4 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-4 
  only A EIF2AK1 Eukaryotic translation initiation factor 2-
alpha kinase 1 
 only B GPR160 Probable G-protein coupled receptor 160 
  only A EIF4EBP2 Eukaryotic translation initiation factor 4E-
binding protein 2 
  SH2B1 SH2B adapter protein 1  
  only A TREML2 Trem-like transcript 2 protein   PPP1R8 Isoform Gamma of Nuclear inhibitor of protein 
phosphatase 1 
  only A ZAK Isoform 2 of Mitogen-activated protein 
kinase kinase kinase MLT  
     
  only A ZFAND6 AN1-type zinc finger protein 6      
  only A NGFRAP1 Isoform 2 of Protein BEX3      
    PTCH1  Isoform S of Protein patched homolog 1         
          
Uncharacterized only A C3orf51 Putative uncharacterized protein C3orf51   only B NCRNA00204 Putative uncharacterized protein CXorf52B 
  only A XKR4 XK-related protein 4  only B PCNXL3 Pecanex-like protein 3 
  only A FAM189A1 Isoform 2 of Protein FAM189A1      
   C9orf43 Uncharacterized protein C9orf43      
   KIAA1671 Uncharacterized protein KIAA1671      
   HEATR8 Maestro heat-like repeat-containing protein 
family member 7 
     
   CCDC77 Coiled-coil domain-containing protein 77      
    MORC4 MORC family CW-type zinc finger protein 
4 
        
          
Others only A ISCU Isoform 2 of Iron-sulfur cluster assembly 
enzyme ISCU, mitochondrial  
  only B C1orf61 Protein CROC-4 
  only A KCTD2 BTB/POZ domain-containing protein 
KCTD2 
  MAT2B Isoform 5 of Methionine adenosyltransferase 2 
subunit beta 
  only A KLHL17 Kelch-like protein 17   CHGB Secretogranin-1;GAWK peptide;CCB peptide 
  only A MAGEC3 MAGEC3 protein    SLC35B3 Adenosine 3-phospho 5-phosphosulfate transporter 
2 
  only A MPDZ Multiple PDZ domain protein   SSFA2 Sperm-specific antigen 2 
  only A SCGB2A1 Mammaglobin-B   AANAT Serotonin N-acetyltransferase  
  only A SPINK5 Isoform long of Serine protease inhibitor 
Kazal-type 5 
  KPRP Keratinocyte proline-rich protein 
  only A AKT1S1 Isoform 3 of Proline-rich AKT1 substrate 1   PDZD4 PDZ domain-containing protein 4 
   LCN10 Epididymal-specific lipocalin-10   EPG5 Ectopic P granules protein 5 homolog 
   UBC;UBB;RPS27A;UBA52 Polyubiquitin-C;Ubiquitin;Polyubiquitin-
B;Ubiquitin..... 
  INADL Isoform 5 of InaD-like protein  
   MFSD9 Major facilitator superfamily domain-
containing protein 9 
     
   IFNA10;IFNA21;IFNA17…. Interferon alpha-10;Interferon alpha-21....      
   RNF223 RING finger protein 223      
   CEP112 Centrosomal protein of 112 kDa      
   LYZ Lysozyme C      
   DCD Dermcidin;Survival-promoting 
peptide;DCD-1 
     
   CALML5 Calmodulin-like protein 5      
   S100A7;S100A7A Protein S100-A7;Protein S100-A7A      
   LETM1 LETM1 and EF-hand domain-containing 
protein 1, mitochondrial 
     
  
   ADAMTS17 A disintegrin and metalloproteinase with 
thrombospondin motifs 17 
     
   GOLM1 Golgi membrane protein 1        
    PIP Prolactin-inducible protein      
Table 1: List of the proteins increased in group B. Proteins were considered increased or decreased if they 
showed significant t-test difference (cut-off at 5% permutation-based False Discovery Rate) between group 
A and B. Previous identification: in the Table the proteins previously identified in human blastocoel fluid 
(16, 17) are indicated with a capital X, while x indicates gene products previously experimentally detected 
at the protein level as secreted and/or present in extracellular region and/or in exosome and/or in 
microvesicles according to public available databases and dataset (www.neXtProt.org, www.exocarta.org, 
microvesicle.org, geneontology.org, www.proteinatlas.org, 29) or at the gene expression level from 
microarray data (16, 92) or at the transcription level in blastocystis or embyonic tissue according to 
http://genomewidepdb.proteomix.org or https://www.ncbi.nlm.nih.gov/geoprofiles databases. The 
proteins ascribed to fertilization and embryo implantation or nucleic acid interaction categories of Fig. 4 are 
highlighted in light and dark grey, respectively. The table lists only the proteins present and quantified in at 
least 3 out of 5 technical repeats using a false positive rate of 0.05 and minimum peptide length 9 amino 
acids, reporting in a column the proteins identified with FDR 0.01. 
Protein 
IDs 
Protein names Gene names t-test 
Difference 
FDR 
1% 
Previous 
identification 
Q96NH3 Protein broad-minded BROMI;C6orf170 1.612  x 
Q9UHD9 Ubiquilin-2 UBQLN2 1.451 X x 
Q9NZL9-5 Isoform 5 of Methionine 
adenosyltransferase 2 subunit beta 
MAT2B 1.217  x 
P05060 Secretogranin-1;GAWK peptide;CCB 
peptide 
CHGB 1.159 X x 
Q9H1N7 Adenosine 3-phospho 5-
phosphosulfate transporter 2 
SLC35B3 0.932  x 
Q6ZU67 BEN domain-containing protein 4 BEND4 0.837  x 
P28290 Sperm-specific antigen 2 SSFA2 0.792 X x 
J3KMZ5 Serotonin N-acetyltransferase AANAT 0.717  x 
H0YNB0 Unconventional myosin-Ie MYO1E 0.712  x 
H3BUN7 SH2B adapter protein 1 SH2B1 0.617 X x 
Q5T749 Keratinocyte proline-rich protein KPRP 0.600 X X 
Q76G19 PDZ domain-containing protein 4 PDZD4 0.582 X x 
Q9HCE0 Ectopic P granules protein 5 homolog EPG5 0.561  x 
Q12972-3 Isoform Gamma of Nuclear inhibitor 
of protein phosphatase 1 
PPP1R8 0.553  x 
G3V314 Ena/VASP-like protein EVL 0.491  x 
Q8NI35-5 Isoform 5 of InaD-like protein INADL 0.450  x 
P14923 Junction plakoglobin JUP 0.445 X x 
 
Table 2: List of the proteins decreased in group B. Proteins were considered increased or decreased if they 
showed significant t-test difference (cut-off at 5% permutation-based False Discovery Rate) between group 
A and B. Previous identification: in the Table the proteins previously identified in human blastocoel fluid 
(16, 17) are indicated with a capital X, while x indicates gene products previously experimentally detected 
at the protein level as secreted and/or present in extracellular region and/or in exosome and/or in 
microvesicles according to public available databases and dataset (www.neXtProt.org, www.exocarta.org, 
microvesicle.org, geneontology.org, www.proteinatlas.org, 29) or at the gene expression level from 
microarray data (16, 92) or at the transcription level in blastocystis or embyonic tissue according to 
http://genomewidepdb.proteomix.org or https://www.ncbi.nlm.nih.gov/geoprofiles databases. The 
proteins ascribed to fertilization and embryo implantation or nucleic acid interaction categories of Fig. 4 are 
highlighted in light and dark grey, respectively. The table lists only the proteins present and quantified in at 
least 3 out of 5 technical repeats using a false positive rate of 0.05 and minimum peptide length 9 amino 
acids, reporting in a column the proteins identified with FDR 0.01. 
Protein 
IDs 
Protein names Gene  names t-test  
Differe
nce 
FDR 
1% 
Previous 
identification 
Q02413 Desmoglein-1 DSG1 -0.158 X X 
J3KNN1 Polypeptide N-acetylgalactosaminyltransferase 9 GALNT9 -0.194 X  
Q8TAL5 Uncharacterized protein C9orf43 C9orf43 -0.341  x 
P22732 Solute carrier family 2, facilitated glucose 
transporter member 5 
SLC2A5 -0.349  x 
P01566 Interferon alpha-10;Interferon alpha-21 IFNA10;IFN
A21 
-0.368 X x 
G8JLG2 Corneodesmosin CDSN -0.379  X 
F8WCM5 Insulin;Insulin B chain;Insulin A chain INS-
IGF2;INS 
-0.386 X X 
Q8NBP5 Major facilitator superfamily domain-containing 
protein 9 
MFSD9 -0.420 X x 
Q13635-4 Isoform S of Protein patched homolog 1 PTCH1 -0.421 X x 
P05109 Protein S100-A8 S100A8 -0.438 X X 
F8W878 Brain-specific angiogenesis inhibitor 1-associated 
protein 2 
BAIAP2 -0.464 X x 
Q9HCJ0 Trinucleotide repeat-containing gene 6C protein TNRC6C -0.476 X x 
Q6JVE6 Epididymal-specific lipocalin-10 LCN10 -0.504  x 
P0CG48 Polyubiquitin-C;Ubiquitin;Polyubiquitin-B UBC;UBB -0.539 X X 
F8W8U3 Homeobox protein Meis1 MEIS1 -0.558  x 
E7ERA6 RING finger protein 223 RNF223 -0.558 X  
Q96F24-
2 
Nuclear receptor-binding factor 2 NRBF2 -0.634 X x 
Q9BY89 Uncharacterized protein KIAA1671 KIAA1671 -0.645  x 
Q8N8E3 Centrosomal protein of 112 kDa CEP112 -0.713  x 
P61626 Lysozyme C LYZ -0.760 X X 
C9K0L2 Maestro heat-like repeat-containing protein family 
member 7 
HEATR8 -0.760 X  
Q6PGQ7 Protein aurora borealis BORA;FLJ22
624 
-0.770 X x 
P81605 Dermcidin;Survival-promoting peptide;DCD-1 DCD -0.793 X X 
Q9NZT1 Calmodulin-like protein 5 CALML5 -0.829  X 
Q9BV73 Centrosome-associated protein CEP250 CEP250 -0.991  X 
O00712 Nuclear factor 1;Nuclear factor 1 B-type NFIB -1.041  x 
O94788-3 Isoform 3 of Retinal dehydrogenase 2 ALDH1A2 -1.065  x 
P19021 Peptidyl-glycine alpha-amidating monooxygenase PAM -1.140  x 
Q6GMR7 Fatty-acid amide hydrolase 2 FAAH2 -1.178 X x 
H0Y7A7 Calmodulin CALM2;CAL
M1 
-1.209 X x 
P31151 Protein S100-A7;Protein S100-A7A S100A7;S100
A7A 
-1.240 X X 
Q96RW7 Hemicentin-1 HMCN1 -1.250 X x 
Q9BR77 Coiled-coil domain-containing protein 77 CCDC77 -1.315 X x 
Q6UWP8 Suprabasin SBSN -1.407 X X 
P31025 Lipocalin-1;Putative lipocalin 1-like protein 1 LCN1;LC
N1P1 
-1.419 X X 
Q9UGM3 Deleted in malignant brain tumors 1 protein DMBT1 -1.508 X X 
O95202 LETM1 and EF-hand domain-containing protein 1, 
mitochondrial 
LETM1 -1.622  x 
D6R956 Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1 -1.796  X 
Q8TE56 A disintegrin and metalloproteinase with 
thrombospondin motifs 17 
ADAMTS
17 
-1.825 X x 
Q8TE76 MORC family CW-type zinc finger protein 4 MORC4 -1.857 X x 
P20382 Pro-MCH;Neuropeptide-glycine-glutamic acid PMCH -2.149 X x 
P01040 Cystatin-A CSTA -2.310 X X 
Q8NBJ4 Golgi membrane protein 1 GOLM1 -2.427 X x 
P12273 Prolactin-inducible protein PIP -2.704 X X 
 
Table 3: List of the proteins present only in group A. Previous identification: in the Table the proteins 
previously identified in human blastocoel fluid (16, 17) are indicated with a capital X, while x indicates gene 
products previously experimentally detected at the protein level as secreted and/or present in extracellular 
region and/or in exosome and/or in microvesicles according to public available databases and dataset 
(www.neXtProt.org, www.exocarta.org, microvesicle.org, geneontology.org, www.proteinatlas.org, 29) or 
at the gene expression level from microarray data (16, 92) or at the transcription level in blastocystis or 
embyonic tissue according to http://genomewidepdb.proteomix.org or 
https://www.ncbi.nlm.nih.gov/geoprofiles databases. The proteins ascribed to fertilization and embryo 
implantation or nucleic acid interaction categories of Fig. 4 are highlighted in light and dark grey, 
respectively. The table lists only the proteins present and quantified in at least 3 out of 5 technical repeats 
using a false positive rate of 0.05 and minimum peptide length 9 amino acids, reporting in a column the 
proteins identified with FDR 0.01. 
Protein 
IDs 
Protein names Gene names FDR 
1% 
Previous 
identification 
P04745 Alpha-amylase 1;Pancreatic alpha-amylase AMY1A;AMY2A  X 
Q13535 Serine/threonine-protein kinase ATR ATR  x 
J9JIC5 Protein Njmu-R1 C17orf75  x 
O76042 Putative uncharacterized protein C3orf51 C3orf51 X  
H0Y7H7 Dedicator of cytokinesis protein 4 DOCK4  x 
B4DIP4 Eukaryotic translation initiation factor 2-alpha 
kinase 1 
EIF2AK1  x 
Q13542 Eukaryotic translation initiation factor 4E-binding 
protein 2 
EIF4EBP2 X x 
Q9H1K1-2 Isoform 2 of Iron-sulfur cluster assembly enzyme 
ISCU, mitochondrial 
ISCU  x 
H0Y3B9 BTB/POZ domain-containing protein KCTD2 KCTD2 X x 
Q7Z4S6 Kinesin-like protein KIF21A KIF21A  x 
Q6TDP4 Kelch-like protein 17 KLHL17  x 
Q9UKR0 Kallikrein-12 KLK12  x 
P11047 Laminin subunit gamma-1 LAMC1  x 
P02788 Lactotransferrin;Kaliocin-1;Lactoferroxin-
A;Lactoferroxin-B;Lactoferroxin-C 
LTF X X 
Q3SYA6 MAGEC3 protein MAGEC3   
F5H1U9 Multiple PDZ domain protein MPDZ X x 
Q96DH6 RNA-binding protein Musashi homolog 2 MSI2  x 
P51843 Nuclear receptor subfamily 0 group B member 1 NR0B1  x 
Q9BSM1 Polycomb group RING finger protein 1 PCGF1 X x 
Q5VWC4 26S proteasome non-ATPase regulatory subunit 4 PSMD4  x 
P46060 Ran GTPase-activating protein 1 RANGAP1  x 
O75556 Mammaglobin-B SCGB2A1  x 
C9JNL6 Electrogenic sodium bicarbonate cotransporter 4 SLC4A5  x 
Q9NQ38 Serine protease inhibitor Kazal-type 5 SPINK5 X x 
Q5T2D2 Trem-like transcript 2 protein TREML2  x 
Q9H3U1 Protein unc-45 homolog A UNC45A  x 
Q5GH76 XK-related protein 4 XKR4 X  
Q9NYL2-2 Isoform 2 of Mitogen-activated protein kinase 
kinase kinase MLT 
ZAK  x 
Q6FIF0 AN1-type zinc finger protein 6 ZFAND6  x 
O60320-2 Isoform 2 of Protein FAM189A1 FAM189A1  x 
Q00994-2 Isoform 2 of Protein BEX3 NGFRAP1  x 
Q96B36-3 Isoform 3 of Proline-rich AKT1 substrate 1 AKT1S1  x 
 
Table 4: List of the proteins present only in group B. Previous identification: in the Table the proteins 
previously identified in human blastocoel fluid (16, 17) are indicated with a capital X, while x indicates gene 
products previously experimentally detected at the protein level as secreted and/or present in extracellular 
region and/or in exosome and/or in microvesicles according to public available databases and dataset 
(www.neXtProt.org, www.exocarta.org, microvesicle.org, geneontology.org, www.proteinatlas.org, 29) or 
at the gene expression level from microarray data (16, 92) or at the transcription level in blastocystis or 
embyonic tissue according to http://genomewidepdb.proteomix.org or 
https://www.ncbi.nlm.nih.gov/geoprofiles databases. The proteins ascribed to fertilization and embryo 
implantation or nucleic acid interaction categories of Fig. 4 are highlighted in light and dark grey, 
respectively. The table lists only the proteins present and quantified in at least 3 out of 5 technical repeats 
using a false positive rate of 0.05 and minimum peptide length 9 amino acids, reporting in a column the 
proteins identified with FDR 0.01. 
Protein 
IDs 
Protein names Gene names FDR 
1% 
Previous 
identification 
A6NKX1 Putative uncharacterized protein CXorf52B NCRNA00204   
O75553-5 Isoform DAB553 of Disabled homolog 1 DAB1  x 
O75665 Oral-facial-digital syndrome 1 protein OFD1  x 
P16104 Histone H2A.x;Histone H2A type 1-A H2AFX;HIST1H2A
A 
X X 
P48431 Transcription factor SOX-2 SOX2 X x 
P51654 Glypican-3;Secreted glypican-3 GPC3  x 
P62805 Histone H4 HIST1H4A X X 
Q05639 Elongation factor 1-alpha 2;Elongation factor 1-
alpha 1;Putative elongation factor 1-alpha-like 3 
EEF1A2;EEF1A1;E
EF1A1P5 
X X 
Q15147 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-4 
PLCB4  x 
Q5J5C9 Beta-defensin 121 DEFB121  x 
Q96DR8 Mucin-like protein 1 MUCL1 X X 
Q96ST8 Centrosomal protein of 89 kDa CEP89  x 
Q9H6A9 Pecanex-like protein 3 PCNXL3  x 
Q9UJ42 Probable G-protein coupled receptor 160 GPR160  x 
B4DR52 Histone H2B;Histone H2B type 1-K HIST2H2BF;HIST1
H2BK 
X X 
H0Y3T1 Protein CROC-4 C1orf61  x 
 




